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Abstract
Background: The prevalence of type 2 diabetes mellitus (T2DM) continues to rise worldwide. More women from
developing countries who are in the reproductive age group have diabetes resulting in more pregnancies
complicated by T2DM, and placing both mother and foetus at higher risk. Management of these risks is best
achieved through comprehensive preconception care and glycaemic control, both prior to, and during pregnancy.
The aim of this review was to compare the quality and content of current guidelines concerned with the
preconception care of women with diabetes and to develop a summary of recommendations to assist in the
management of diabetic women contemplating pregnancy.
Methods: Relevant clinical guidelines were identified through a search of several databases (MEDLINE, SCOPUS and
The Cochrane Library) and relevant websites. Five guidelines were identified. Each guideline was assessed for
quality using the AGREE instrument. Guideline recommendations were extracted, compared and contrasted.
Results: All guidelines were assessed as being of high quality and strongly recommended for use in practice. All
were consistent in counselling about the risk of congenital malformation related to uncontrolled blood sugar
preconceptionally, ensuring adequate contraception until glycaemic control is achieved, use of HBA1C to monitor
metabolic control, when to commence insulin and switching from ACE inhibitors to other antihypertensives. Major
differences were in the targets recommended for optimal metabolic control and opinion regarding the usage of
metformin as an adjunct or alternative treatment before or during pregnancy.
Conclusions: International guidelines for the care of women with diabetes who are contemplating pregnancy are
consistent in their recommendations; however some are more comprehensive than others. Having established
current standards for the preconception care of diabetic women, there is now a need to focus on guideline
implementation through an examination of the barriers and enablers to successful implementation, and the
applicability of the recommendations in the local setting.
Background
The prevalence of type 2 diabetes mellitus (T2DM) con-
tinues to rise worldwide [1,2], with population based
studies reporting increases in Malaysia [3], the UK [4],
the USA [5], Europe [6] and Australia [7]. In developed
countries, more than half of all people with diabetes are
older than 65 years, and only 8% of adults with diabetes
are younger than 44. In contrast, three quarters of peo-
ple affected by diabetes in developing countries are
under 65 years old, and 25% of all adults with diabetes
are younger than 44 [8]. Thus more women of repro-
ductive age in developing countries have diabetes,
resulting in an increased number of pregnancies compli-
cated by T2DM [9-11] placing both mother and foetus
at higher risk of morbidity and mortality [12].
Diabetes in pregnancy is associated with higher rates
of miscarriage, pre-eclampsia, preterm labour and higher
rates of fetal malformation [13]; neural tube defect, urin-
ary tract disorder, macrosomia, birth injury, and perina-
tal mortality [14]. These risks can be minimised by
optimal glycaemic control, both prior to and throughout
the pregnancy [15,16], andi sb e s ta c h i e v e dt h r o u g h
comprehensive preconception care where other issues
such as genetic risks, health status, reproductive history,
exposure to environment toxins, immunisation and life-
style risk factors can also be addressed through a * Correspondence: danielle.mazza@med.monash.edu.au
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ment of diabetes before and during pregnancy [17,18].
Two previous guideline comparisons for the care of
pregnant women (including preconception care) with
diabetes exist [19,20]. The first was a comparison of
international and New Zealand guidelines. This study
reported a variation in recommendations for folate sup-
plementation with the dose ranging from 0.4 mg to 5
mg and while the authors comment that the other pre-
conceptional recommendations were broadly similar, the
guidelines lacked contraceptive advice, specification of
HbA1C targets and recommendations regarding medica-
tion review. The second review was conducted by the
Centers for Disease Control (CDC); however, this review
was restricted to guidelines available in the United
States. The aim of this current review was to compare
the quality and content of current national and interna-
tional guidelines that are concerned with the preconcep-
tion care of women with diabetes, and to develop a
summary of recommendations to assist in the manage-
ment of diabetic women contemplating pregnancy.
Methods
A systematic search was conducted of databases (Ovid
Medline, the Cochrane Library, SCOPUS), guideline
websites (clinical guidelines on Medical Journal of Aus-
tralia website, Scottish Intercollegiate Guidelines Net-
work, National Institute for Health and Clinical
Evidence, New Zealand Guidelines Group, National
Guideline Clearinghouse (US)) and other relevant web-
sites (the American Diabetes Association, the Australa-
sian Diabetes in Pregnancy Society, the Royal Australian
College of General Practitioners and the Royal Austra-
lian and New Zealand College of Obstetricians and
Gynaecologists). Search terms included: preconception
care, pre conception care, preconception health, pre
conception health, preconception, pre conception, pre-
pregnancy care, pre pregnancy care, type 2 diabetes, dia-
betes mellitus and guidelines.
Our inclusion criteria were national and international
English language guidelines published from 2001 to May
2009. We excluded those that were local or hospital
based. Five guidelines that matched the criteria were
identified [21-25]. Each guideline was scored for guide-
line quality by two independent appraisers using the
AGREE instrument [26]. Differences were discussed and
resolved. We compared and contrasted the guideline
recommendations under the headings of: management
approach, evaluation of previous medical and obstetric
history, evaluation and treatment of diabetic complica-
tions, review of current medication, assessment of meta-
bolic control, blood glucose management, folate
supplementation, preconception counselling, contraindi-
cations to pregnancy and thyroid screening (Table 1).
From this, we developed a summary of preconception
care recommendations for use by practising physicians.
Results
Of the five guidelines identified, two were from the
American Diabetes Association (ADA) (ADA 2009 [21]
and ADA 2004 [22]). The ADA 2009 is the generic
guideline for medical care in diabetes with a specific
chapter on pre-conception care, whereas the ADA 2004
guideline is focussed on preconception care of women
with diabetes. The remaining guidelines were produced
by the National Institute for Health and Clinical Excel-
lence (NICE) (NICE 2008 [23]), the Scottish Intercollegi-
ate Guideline Network (SIGN) (SIGN 2001 [24]), and
the Australasian Diabetes in Pregnancy Society (ADIPS)
(ADIPS 2005[25]).
Comparison of guideline quality
All guidelines were rated as being of high quality and
strongly recommended for use in practice using the
AGREE instrument. Scores for individual guidelines
using the AGREE instrument are given in Table 2.
Comparison of guideline recommendations
Management approach and evaluation of previous medical
and obstetric history
All the practice guidelines agree that diabetic women
contemplating pregnancy should be seen by a multidis-
ciplinary team; however this was not specifically men-
tioned by the NICE guidelines. Both the ADA 2009 and
the SIGN guidelines recommend undertaking a com-
plete preconception evaluation of the women’s medical
and obstetric history.
Evaluation and treatment of diabetic complications
Evaluating and treating diabetic retinopathy is recom-
mended by all the guidelines and nephropathy by all
except SIGN. The ADA and ADIPS guidelines also
recommend an assessment of neuropathy and undertak-
ing a cardiovascular assessment prior to conception.
Specifically assessing the women for hypertension is
only recommended by ADA 2004 and SIGN with the
latter nominating a target blood pressure (BP) of < 140/
80 for women with diabetic nephropathy.
Review of current medication
Undertaking a medication review before a diabetic
woman gets pregnant is recommended by all the guide-
lines except NICE. While stopping Angiotensin-Con-
verting Enzyme (ACE) inhibitors is mentioned by all,
some guidelines also recommend stopping statins
[21,23,25] and angiotensin-II receptor antagonists (ARB)
[21,23]. The ADA 2004 also recommends stopping
diuretics and b-blockers.
Assessment of metabolic control and blood glucose
management
Monitoring metabolic control using HbA1C and achiev-
ing a target of < 7% is recommended by all guidelines.
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ADA
2009
ADA
2004
NICE
2008
SIGN
2001
ADIPS
2005
Management by multidisciplinary team ✓✓ ✓ ✓
Complete preconception evaluation of
medical and obstetric history
✓✓
Evaluation and treatment of diabetic
complications
retinopathy ✓✓ ✓ ✓ ✓
nephropathy ✓✓ ✓ ✓
neuropathy ✓✓ ✓
cardiovascular disease ✓✓ ✓
hypertension ✓✓
target BP
should
be < 140/80
Medication review
Review all current medication ✓✓ ✓ ✓
Stop Angiotensin-Converting Enzyme
(ACE) inhibitors
✓✓ ✓ ✓ ✓
Stop Angiotensin-II Receptor Blockers
(ARB)
✓✓ ✓
Stop statins ✓✓ ✓
Stop diuretics ✓
Stop b-blockers ✓✓ ✓
Assessment of metabolic control
Measure Use HbA1C Use HbA1C Use HbA1C Use HbA1C Use HbA1C
Frequency of testing 1-2 monthly
Target level < 7% Up to 1% above normal
value, lower if possible
< 6.1% optimised
HbA1C
<7 %
Blood glucose management
Self monitoring targets Before meals 4.4-6.1
mmol/l, 2 hours after
meal <8.6 mmol/l
Between 4 and
7 mmol/L
Educate regarding hypoglycaemia
awareness and management
✓✓
Prescribe insulin to achieve target blood
glucose levels
✓✓ ✓ ✓ ✓
Use metformin as an adjunct or
alternative
✓✓ ✓
Folate supplementation
Commencement preconception preconception Preconception
Dose 5 mg/day 5 mg/day 5 mg/day
Duration until 12 weeks
gestation
until 12 weeks
gestation
Preconception Counselling
should be routinely
incorporated into
diabetic care
is essential
Advise of risk of malformation with poor
metabolic control and unplanned
pregnancy
✓✓ ✓ ✓ ✓
Advise use of effective contraception
until good glucose control is achieved
before conception
✓✓ ✓ ✓ ✓
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cose self monitoring is another important recommenda-
tion by most of the guidelines apart from ADA 2009 or
the ADIPS 2005 guidelines. The ADA 2004 defines a
target pre-meal blood glucose level of between 4.4-6.1
mmol/L and 2 hours after meals <8.6 mmol/L. All
guidelines, except for the ADA 2009, confirm that blood
sugar levels should be maintained as normal as possible
whilst avoiding hypoglycaemia. Both the NICE and
ADIPS guidelines advocate teaching the patient and
partner about hypoglycaemia awareness and manage-
ment [23,25].
All guidelines recommend prescribing insulin precon-
ceptionally to achieve target levels of blood glucose. Use
of metformin as an adjunct or alternative for diabetic
treatment preconceptionally when insulin treatment is
refused or a patient develops resistance, is recom-
mended by the more recent guidelines [21,23,25].
Folate supplementation
Folate supplementation with a daily dose of 5 mg is
recommended by three of the guidelines for those plan-
ning to become pregnant up until 12 weeks gestation.
ADIPS does not mention the duration of treatment.
Both ADA 2009 and ADA 2004 fail to mention the
importance of folate supplementation.
Preconception counselling
The routine incorporation of preconception counsel-
ling into diabetic clinic visits for all women of child-
bearing potential is recommended by ADA 2009. All
guidelines recommend that diabetic women should
receive counselling about the effective use of contra-
ception in order to plan pregnancies, and the risk of
malformation with poor metabolic control and
unplanned pregnancy. Informing the patient about
how Diabetes Mellitus (DM) affects pregnancy and
how pregnancy affects DM is recommended by two
guidelines [22,23]. Other important preconception
issues like smoking cessation and reducing alcohol
intake is only recommended by ADIPS 2005. ADIPS
recommends weight management and exercise as gen-
eral pre-pregnancy advice and NICE recommends
w e i g h tr e d u c t i o nf o rw o m e nw i t haB M I> 2 7k g / m
2.
Provision of dietary advice such as consuming a diet
with high levels of complex carbohydrates, soluble
fibre and vitamins, and reduced levels of saturated fats
is also recommended [23,24].
Contraindications to pregnancy
The NICE guideline states that an HbA1C > 10% is a
contraindication to pregnancy. In contrast ADIPS sug-
gests that impaired renal function as measured by a
serum creatinine > 0.2 mmol/L should be a contraindi-
cation to pregnancy.
Thyroid screening
Thyroid function screening is recommended by ADA
2004 and ADIPS for women with Type 1 diabetes but
not T2DM.
A summary of preconception care recommendations
for diabetic women is provided in Table 3.
Table 2 AGREE final scores for identified guidelines
ADA 2009 ADA 2004 NICE 2008 SIGN 2001 ADIPS 2005
Scope and Purpose 94% 100% 100% 100% 94%
Stakeholder involvement 96% 50% 50% 75% 50%
Rigour of development 71% 71% 100% 100% 71%
Clarity and presentation 96% 100% 100% 100% 83%
Applicability 100% 100% 100% 67% 67%
Editorial independence 50% 50% 50% 50% 50%
Table 1: A comparison of international guidelines recommendation for preconception care among diabetes (Continued)
Inform woman about how DM affects
pregnancy and how pregnancy affects
DM
✓✓
Encourage smoking cessation ✓
Encourage reduction in alcohol intake ✓
Provide dietary advice ✓✓
Advice about weight reduction Aim for a BMI
<2 7
Encourage weight
management and
exercise
Contraindications to pregnancy HbAIC > 10% Creatinine > 0.2
mmol/L
Measure thyroid function in women
with Type 1 DM
✓✓
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A key finding of this review is that all the guidelines
selected for comparison are of high quality and highly
recommended for use in practice. Secondly, the guide-
lines share consistency regarding counselling about the
risk of congenital malformation related to uncontrolled
blood sugar preconceptionally and the use of effective
contraception until good blood sugar control is
achieved. Despite general agreement in all categories of
recommendations, there is a lack of specific practice
based recommendations in certain areas. These include
which type of contraception is most suitable and how
long before conception folate supplementation should
be started. While medication review and advice to stop
ACE inhibitors is consistently given by all the guidelines,
alternative antihypertensives that are safe in pregnancy
are only suggested by ADIPS, however, there is consid-
erable evidence supporting the use of methyldopa,
oxprenolol, clonidine, labetalol, prazosin and nifedipine
in pregnancy [27].
Key differences observed in the recommendations are
target levels of HbA1C to be achieved prior to preg-
nancy. Aiming the HbA1C level at <1% above the upper
limit of normal (generally <7%) is recommended
[21,22,24,25,28] in preparation for pregnancy. However,
there is evidence of better outcomes if the HbA1C is
Table 3 Summary of recommendations for preconception care among diabetic women
Utilise a multidisciplinary team to manage preconception care issues
Members of the team may include an obstetrician, endocrinologist, family physician, diabetic educator and dietician
Complete a full medical and obstetric evaluation in the preconception period to assess risks
Evaluate and treat diabetic complications including:
Retinopathy (pre-existing retinopathy may progress rapidly in pregnancy and should be treated first before pregnancy)
Nephropathy (patients with pre-existing microalbuminuria are more likely to develop pre-eclampsia)
Neuropathy
Cardiovascular disease
Hypertension
Review all current medication use including complementary medication and change the following to a form of therapy which has less risk:
Angiotensin-Converting Enzyme (ACE) inhibitors
Angoitensin-II Receptor Blockers (ARB)
Statins
Diuretics
b-blockers
Assess level of metabolic control
Measure HbA1C monthly until control is achieved
HbA1C should remain below 7% (1% above normal value), lower if possible
Blood glucose management
Undertake blood glucose self monitoring with targets pre-meal of 4.4-6.1 mmol/l and 2 hour after meal of < 8.6 mmol/l
Maintain blood sugar within normal range without hypoglycaemia
Educate on hypoglycaemia awareness and management
Insulin should be prescribed to achieve target blood glucose levels
Use metformin as an adjunct or alternative
Counselling
Commence folate supplementation 5 mg daily pre-conceptually until 12 weeks gestation to prevent neural tube defects
Inform about risk of miscarriage, congenital malformation and perinatal mortality with poor metabolic control and unplanned pregnancy
Inform about how DM affects pregnancy and how pregnancy affects DM
Use effective contraception until target blood glucose control is achieved before conception
Encourage smoking cessation and reduction in alcohol intake
Encourage regular exercise and management of weight to achieve a BMI < 27
Encourage diet with high levels of complex carbohydrates, soluble fibre and vitamins and reduced levels of saturated fats
Contraindications to pregnancy
HbA1C >10%
Impaired renal function, creatinine > 0.2 mmol/L (increased risk of progression to dialysis during pregnancy)
Measure thyroid function in women with Type 1 Diabetes
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early pregnancy [29,30]. In view of this, NICE has cho-
sen the lower value at HbA1C as < 6.1% as a target.
Blood glucose self monitoring is recommended by all
the guidelines; however the target levels are again differ-
ent. When considering the two suggested targets, it may
be more helpful to women to use the more specific one
(pre-meal at between 4.4-6.1 mmol/l and 2 hour after
meal < 8.6 mmol/l [22]).
Deterioration of diabetic complications is another con-
cern in pregnancy among diabetic women [31]. As
recommended by all guidelines, evaluating and treating
diabetic complications are important actions to under-
take before conception. However, not all guidelines out-
line all the possible complications that need to be
evaluated. This may lead to inconsistency in practice
amongst physicians.
The other obvious differences in the recommendations
are in the use of oral hypoglycaemic agents. Though the
safety of currently available oral antidiabetic agents
(metformin and glyburide) during pregnancy looks pro-
mising, the complete safety and efficacy profile during
the full term of pregnancy has not yet been established
[32-34]. As such it is recommended to be used as an
alternative by ADA 2009, ADIPs and NICE in situations
such as refusal of the patient to use insulin or insulin
resistance, when the likely benefits from improved gly-
caemic control outweigh the potential for harm [35].
Counselling is a major component of preconception
care. The feasibility of routine incorporation into all
practice visits need to be considered. Diabetic women
are more likely to be engaged with health system and
therefore there are more opportunities for delivery of
preventive care. On top of specific counselling for dia-
betic women with pregnancy, general preconception
care [36] for women should not be forgotten and should
include depression screening, genetic and family history
risk assessment, immunisation, smoking cessation
advice, advice regarding reducing alcohol intake, weight
management and exercise.
A strength of this review is that all guidelines reviewed
in this series are of high quality and highly recom-
mended to be used as practice guidelines according to a
respected and validated assessment tool- the AGREE
instrument [26]. The limitation of this review is the
omission of non-English language guidelines.
Conclusions
International guidelines for the care of women with dia-
betes who are contemplating pregnancy are consistent
in their recommendations; however, some are more
comprehensive than others. Having established current
recommendations for the preconception care of diabetic
women, there is now a need to focus on guideline
implementation. More work is needed to look at the
applicability of the recommendations in the local setting,
and to specifically examine what barriers and enabling
factors exist to ensure successful implementation.
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